CG Oncology Reports First Results From CORE‑008 Cohort CX Phase 2 Trial

- High CR rates at any time observed in the CIS-containing population with 85.7% and 92.3% in the ITT population and Efficacy Evaluable population, respectively

- High-Grade - EFS in the overall intention-to-treat population was 96.0% at 3 months and 89.5% at 6 months

- Efficacy was comparable across concurrent and sequential treatment arms and across both BCG-exposed and BCG-Unresponsive populations